Various studies have shown that some pore-blocking inhibitors of IK channels improved pathological conditions in immune-related diseases such as asthma, allergic rhinitis, inflammatory bowel disease, and rheumatoid arthritis [153,154,155,156]. This evidence concerns the gene IK and asthma.